Equities

QuantumPharm Inc

QuantumPharm Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)13.10
  • Today's Change0.06 / 0.46%
  • Shares traded5.51m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,8253,4683,829
Total Receivables, Net586147
Total Inventory------
Prepaid expenses9.30155.04
Other current assets, total525339
Total current assets2,9453,5973,920
Property, plant & equipment, net584410287
Goodwill, net------
Intangibles, net7.876.685.12
Long term investments468303170
Note receivable - long term------
Other long term assets------
Total assets4,0064,3164,382
LIABILITIES
Accounts payable141411
Accrued expenses1029374
Notes payable/short-term debt000
Current portion long-term debt/capital leases1196040
Other current liabilities, total633037
Total current liabilities297198161
Total long term debt10,9189,3907,794
Total debt11,0369,4507,834
Deferred income tax------
Minority interest26185.39
Other liabilities, total323831
Total liabilities11,2739,6447,991
SHAREHOLDERS EQUITY
Common stock0.050.050.05
Additional paid-in capital4.594.594.59
Retained earnings (accumulated deficit)(6824)(4978)(3717)
Treasury stock - common(0.02)(0.02)(0.02)
Unrealized gain (loss)------
Other equity, total(448)(354)103
Total equity(7267)(5328)(3609)
Total liabilities & shareholders' equity4,0064,3164,382
Total common shares outstanding3,4073,4073,407
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.